FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause
View all alerts
Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

bromfenac (DURACT)


WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Inadvertent Adverse Reactions With Commonly Used Drugs
January 2012
Find out how to prevent emergency hospitalizations from two commonly used drugs, warfarin (COUMADIN) and clopidogrel (PLAVIX). There are approximately 33,000 emergency hospitalizations a year from warfarin alone. This article includes a list of more than 50 drugs that can have harmful interactions with warfarin and/or clopidogrel.
Blockbuster Arthritis Drug Rofecoxib (VIOXX) Withdrawn From Market
November 2004
Vioxx is the ninth prescription drug to be taken off the market in the past seven years that Worst Pills, Best Pills News readers were previously warned DO NOT USE. The average time between warning readers not to use these drugs and their removal from the market was one year and eight months.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion.

Congress Must Act Quickly to Address Growing Crisis At the Food and Drug Administration
The Food and Drug Administration (FDA) is suffering from a crisis in leadership, a lack of congressional oversight and a dangerous reliance on the pharmaceutical industry to bankroll its operations, Sidney M. Wolfe, M.D., director of the Health Research Group at Public Citizen told a House of Representatives subcommittee this morning.
Comments on FDA's Draft Guidance for Industry - Drug-Induced Liver Injury: Premarketing Clinical Evaluation (HRG Publication #1833)
The FDA's guidance document confirms the agency's continued reluctance to seriously and publicly engage in post-mortem analyses of the growing number of mistakes the FDA has made concerning failed decision-making about either the approval of known hepatotoxic drugs or the dangerously delayed removal of ones showing hepatotoxicity shortly after approval.
Statement Before the Institute of Medicine Committee Assessing the U.S. Drug Safety System (HRG Publication #1759)
Testimony on the adequacy and conclusions of FDA’s pre-approval review and ongoing post-approval reviews.
Testimony to FDA on Dangers of Cox-2 Drugs (HRG Publication #1725)
Testimony of Sidney M. Wolfe, M.D. Director, Public Citizen’s Health Research Group (HRG) Before FDA Arthritis and Drug Safety Advisory Committees Concerning the Dangers of COX-2 Drugs
Comments on: The Prescription Drug User Fee Act (PDUFA) (HRG Publication #1606)
Public Citizen=s position was then, and remains, that Congress must adequately fund the FDA using public money. Also, PDUFA=s second re-authorization in 1997, with its slavish deadlines and the accompanying ill-advised Food and Drug Administration Modernization Act (FDAMA) are examples of failed experiments in public policy.
Letter to the Food and Drug Administration to immediately ban the antibiotic trovafloxacin (Trovan). (HRG Publication #1485)
we hereby petition the Food and Drug Administration (FDA) as authorized by 21 U.S.C. , section 355 (e) of the Federal Food, Drug and Cosmetic Act to immediately ban the widely-used antibiotic, TROVAN (trovafloxacin, Pfizer), before more patients die, require a liver transplant or are otherwise injured from liver toxicity caused by this drug.

Show primary search results for bromfenac (DURACT)

Disclaimer

The information on this website is not intended to substitute for professional medical advice, diagnosis, or treatment. Consult your doctor before changing or discontinuing any medication.